OR WAIT 15 SECS
© 2020 MJH Life Sciences and Drug Topics. All rights reserved.
© 2020 MJH Life Sciences™ and Drug Topics. All rights reserved.
November 17, 2020
“This first-generation polypill is not magic, but it would be clinically worthwhile.”
October 29, 2020
Of the nearly 3 million Americans included in the study, just 1.4% had the flu vaccine and 1.4% had the pneumonia vaccine.
October 20, 2020
The meta-analysis accrued data from 18 studies that focused on patients with hospitalized and chronic heart failure.
September 18, 2020
Data showed that empagliflozin with standard of care was superior to placebo in reducing the risk of CV death or hospitalization.
A study compared cardiac events associated with azithromycin versus amoxicillin.
September 10, 2020
The study investigators used artificial intelligence to analyze gut microbiome data in individuals with and without cardiovascular disease.
September 08, 2020
Approval was based on a phase 3 clinical trial comparing the investigative doses with the approved 1.5 mg dose.
September 03, 2020
There is no evidence that blood pressure lowering drugs increase the risk of cancer, according to a major new study.
August 31, 2020
Dapagliflozin (Farxiga; AstraZeneca) demonstrated positive results in the phase 3 DAPA-CKD trial.
July 31, 2020
Empagliflozin (Jardiance; Eli Lilly) met the primary end point of a study for adults with heart failure with reduced ejection fraction with or without diabetes.